{"id":55584,"date":"2025-11-05T03:08:19","date_gmt":"2025-11-05T07:08:19","guid":{"rendered":"https:\/\/stockmarketwatch.com\/stock-market-news\/mixed-fortunes-in-q3-2025-novo-nordisk-misses-bmw-delivers-mixed-results\/55584\/"},"modified":"2025-11-05T03:08:19","modified_gmt":"2025-11-05T07:08:19","slug":"mixed-fortunes-in-q3-2025-novo-nordisk-misses-bmw-delivers-mixed-results","status":"publish","type":"post","link":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/mixed-fortunes-in-q3-2025-novo-nordisk-misses-bmw-delivers-mixed-results\/55584\/","title":{"rendered":"Mixed Fortunes in Q3 2025: Novo Nordisk Misses, BMW Delivers Mixed Results"},"content":{"rendered":"<h2>Key Takeaways<\/h2>\n<ul>\n<li><strong>Novo Nordisk<\/strong> (<a href=\"\/stock\/NVO\">NVO<\/a>) reported a significant miss across key financial metrics for Q3 2025, with <strong>revenue of DKK 74.98 billion<\/strong> and <strong>net income of DKK 20.01 billion<\/strong> both falling short of analyst expectations.<\/li>\n<li><strong>BMW<\/strong> (<a href=\"\/stock\/BMW.DE\">BMW.DE<\/a>) delivered a mixed Q3 2025 performance, as <strong>revenue of \u20ac32.3 billion<\/strong> missed estimates, but <strong>net profit climbed to \u20ac1.7 billion<\/strong> and <strong>Automotive EBIT Margin reached 5.2%<\/strong>, both surpassing expectations.<\/li>\n<li>Despite the mixed results, <strong>BMW<\/strong> (<a href=\"\/stock\/BMW.DE\">BMW.DE<\/a>) reaffirmed its full-year outlook, confirming its adjusted targets and maintaining its <strong>Automotive EBIT Margin forecast of 5%\u20136%<\/strong>.<\/li>\n<\/ul>\n<h2>Novo Nordisk&#39;s Q3 Falls Short Across Key Metrics<\/h2>\n<p>Pharmaceutical giant <strong>Novo Nordisk<\/strong> (<a href=\"\/stock\/NVO\">NVO<\/a>) experienced a challenging third quarter, with its earnings report revealing misses across several critical financial indicators. The company reported <strong>revenue of DKK 74.98 billion<\/strong>, falling below the estimated DKK 76.68 billion. Similarly, <strong>net income<\/strong> for the quarter stood at <strong>DKK 20.01 billion<\/strong>, missing the DKK 20.82 billion estimate.<\/p>\n<p>Further indicating a softer performance, <strong>EBIT<\/strong> came in at <strong>DKK 23.68 billion<\/strong> against an estimated DKK 25.61 billion, and <strong>pretax profit<\/strong> was <strong>DKK 25.52 billion<\/strong> compared to an estimated DKK 26.42 billion. The company&#39;s <strong>gross margin<\/strong> also saw a decline, reaching <strong>76.1%<\/strong> against an estimated <strong>81.1%<\/strong>. While specific estimates for <em>Wegovy<\/em> sales were not fully disclosed, the reported <strong>DKK 20.35 billion<\/strong> in sales for the popular weight-loss drug was noted.<\/p>\n<h2>BMW Navigates Mixed Q3 with Profit Beat<\/h2>\n<p><strong>BMW<\/strong> (<a href=\"\/stock\/BMW.DE\">BMW.DE<\/a>) presented a more nuanced picture for its Q3 2025 earnings, with some key metrics exceeding expectations despite a revenue miss. The luxury automaker reported <strong>revenue of \u20ac32.3 billion<\/strong>, which was below the consensus estimate of \u20ac33.8 billion. Automotive revenue specifically came in at <strong>\u20ac28.51 billion<\/strong>, slightly missing the \u20ac28.77 billion estimate.<\/p>\n<p>However, the company showcased strong profitability, with <strong>Group EBIT<\/strong> matching estimates at <strong>\u20ac2.26 billion<\/strong>. Notably, <strong>BMW&#39;s net profit<\/strong> soared to <strong>\u20ac1.7 billion<\/strong>, significantly beating the estimated \u20ac1.5 billion. The <strong>Automotive EBIT Margin<\/strong> also impressed, reaching <strong>5.2%<\/strong> and surpassing the 4.9% estimate.<\/p>\n<h2>Full-Year Outlook Confirmed Amidst R&amp;D Focus<\/h2>\n<p>Despite the mixed Q3 results, <strong>BMW<\/strong> (<a href=\"\/stock\/BMW.DE\">BMW.DE<\/a>) confirmed its adjusted full-year targets, which were initially announced in October. The company reiterated its forecast for the <strong>full-year Automotive EBIT Margin<\/strong> to remain within the <strong>5%\u20136%<\/strong> range. This reaffirmation signals management&#39;s confidence in achieving its strategic objectives for the remainder of the year, even as it continues to invest in <strong>R&amp;D and Capex<\/strong>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key Takeaways Novo Nordisk (NVO) reported a significant miss across key financial metrics for Q3 2025, with revenue of DKK [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":50383,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"rank_math_schema_Article":[],"rank_math_focus_keyword":[],"rank_math_description":[],"financial_data_references":[],"stock_symbols_mentioned":[],"footnotes":""},"categories":[5012],"tags":[1807,3744,5089,5199,5211,5775,6334,8043],"class_list":["post-55584","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-breaking-news","tag-earnings","tag-nvo","tag-bmw-de","tag-automotive","tag-bmw","tag-pharmaceuticals","tag-novo-nordisk","tag-q3-2025"],"_links":{"self":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/55584","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/comments?post=55584"}],"version-history":[{"count":0,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/55584\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media\/50383"}],"wp:attachment":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media?parent=55584"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/categories?post=55584"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/tags?post=55584"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}